ClinicalTrials.gg
CompletedNCT05194124Updated Nov 26, 2024Results posted

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

A Phase 3 interventional study of Setmelanotide 2 mg and Setmelanotide 2.5 mg in Bardet-Biedl Syndrome and POMC Deficiency, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 7 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Study summary

A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.

Read the detailed description

This study is designed to compare the safety, pharmacokinetics, and efficacy of weekly and daily formulations of setmelanotide in participants with obesity associated with biallelic or heterozygous POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase subtilisin/kexin Type 1), LEPR (leptin receptor) genetic variants, and participants with Bardet-Biedl Syndrome (BBS).

02

Conditions studied

  • Bardet-Biedl Syndrome
  • POMC Deficiency

Keywords

  • Melanocortin-4 Receptor Pathway
  • Genetic Obesity
  • Hunger
  • Hyperphagia
03

In context

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Biallelic or heterozygous POMC/PCSK1 or LEPR (PPL) genetic variants or Bardet-Biedl syndrome (BBS), for which they are being treated with QD setmelanotide.
  • 6 years or older at screening.
  • Taking the setmelanotide QD formulation for at least 6 months in the RM-493-022 (NCT03013543) study with acceptable safety and tolerability, and dose level.
  • Participant and/or parent or guardian is able to communicate well with the Investigator, to understand and comply with the requirements of the study and is able to understand and sign the written /assent.
  • Use of a highly effective form of throughout the study and for 90 days following the study.

Key Exclusion Criteria:

  • Glycosylated () >9.0% at screening.
  • Anti-obesity medications within 3 months prior to starting the Run-in Period.
  • History of significant liver disease or liver injury.
  • \<30 milliliter per minute (mL/min).
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.
  • Major psychiatric disorders.
  • Any suicidal ideation or behavior, or any lifetime history of a suicide attempt.
  • Significant to any in the study drug.
  • Inability to comply with the QW and QD injection regimens.
  • Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing, with the exception of a setmelanotide clinical trial.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Run-in Period: Setmelanotide 2 mg QD

    Participants received subcutaneous (SC) injection of 2 mg setmelanotide once daily (QD) for 1 week in the run-in period.

    Drug: Setmelanotide 2 mg

  • Experimental
    Run-in Period: Setmelanotide 2.5 mg QD

    Participants received SC injection of 2.5 mg setmelanotide QD for 1 week in the run-in period.

    Drug: Setmelanotide 2.5 mg

  • Experimental
    Run-in Period: Setmelanotide 3 mg QD

    Participants received SC injection of 3 mg setmelanotide QD for 1 week in the run-in period.

    Drug: Setmelanotide 3 mg

  • Experimental
    DB Period: Setmelanotide 20 mg QW

    Participants who received 2 mg setmelanotide QD in the run-in period, received SC injection of 20 mg setmelanotide once weekly (QW) and placebo matched to setmelanotide QD for 13 weeks in the DB period.

    Drug: Setmelanotide 20 mg

  • Experimental
    DB Period: Setmelanotide 25 mg QW

    Participants who received 2.5 mg setmelanotide QD in the run-in period, received SC injection of 25 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.

    Drug: Setmelanotide 25 mg

  • Experimental
    DB Period: Setmelanotide 3 mg QD

    Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 3 mg setmelanotide QD and placebo matched to setmelanotide QW for 13 weeks in the DB period.

    Drug: Setmelanotide 3 mg

  • Experimental
    DB Period: Setmelanotide 30 mg QW

    Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 30 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.

    Drug: Setmelanotide 30 mg

  • Experimental
    OL Period: Setmelanotide 20 mg QW

    Participants who received 2 mg setmelanotide QD in the run-in period and 20 mg setmelanotide QW in the DB period, received SC injection of 20 mg setmelanotide QW for 13 weeks in the OL period.

    Drug: Setmelanotide 20 mg

  • Experimental
    OL Period: Setmelanotide 25 mg QW

    Participants who received 2.5 mg setmelanotide QD in the run-in period and 25 mg setmelanotide QW in the DB period, received SC injection of 25 mg setmelanotide QW for 13 weeks in the OL period.

    Drug: Setmelanotide 25 mg

  • Experimental
    OL Period: Setmelanotide 30 mg QW

    Participants who received 3 setmelanotide QD in the run-in period and 3 mg setmelanotide QD or 30 mg setmelanotide QW in the DB period, received SC injection of 30 mg setmelanotide QW for 13 weeks in the OL period.

    Drug: Setmelanotide 30 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period

    Maximum drug concentration determined directly from individual concentration-time data.

    Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1

  2. Cmax of Setmelanotide After QW Administration

    Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14

  3. Time to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period

    Maximum drug concentration determined directly from individual concentration-time data.

    Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1

  4. Tmax of Setmelanotide After QW Administration

    Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14

  5. Mean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 1

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 1

  6. Mean Setmelanotide Ctrough After QD or QW Administration at Week 5

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 5

  7. Mean Setmelanotide Ctrough After QD or QW Administration at Week 9

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 9

  8. Mean Setmelanotide Ctrough After QD or QW Administration at Week 18

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 18

  9. Mean Setmelanotide Ctrough After QD or QW Administration at Week 22

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 22

  10. Mean Setmelanotide Ctrough After QD or QW Administration at Week 27

    Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: 30 minutes predose at Week 27

  11. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period

    AUC0-tau was recorded from collected blood samples.

    Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, and 8 hours postdose at Week -1

  12. AUC0-tau of Setmelanotide After QD Administration in the Run-in Period

    AUC0-tau was recorded from collected blood samples. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

    Time frame: Pre-dose (0 hour) and 0.5, 1, 2, 6, 8, 12, 24, 48, 72, 96, 120, and 168-hours postdose at Week 14

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The AEs reported after the start of the run-in period were considered TEAEs.

    Time frame: From first dose of study drug administration up to Week 30

  2. Number of Participants With Injection Site Reactions (ISRs) From Baseline Through Week 13

    The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Baseline was defined as the last available measurement prior to the first dose of setmelanotide or placebo. Injection site reactions frequency of once daily (QD) and once weekly (QW) were reported. Data are reported by dose level (treatment regimen) in the DB Period. Number of participants with injection site reactions according to severity were reported.

    Time frame: Baseline through Week 13

  3. Number of Participants With ISRs From Week 14 Through Week 27

    The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Injection site reactions frequency of QD and QW were reported. Data are reported by dose level (treatment regimen) in the OL Period. Number of participants with injection site reactions according to severity were reported.

    Time frame: Week 14 through Week 27

07

Results

Posted Nov 26, 2024

Participant flow

Run-in Period (1 Week)
Participant flow — Run-in Period (1 Week)
MilestoneRun-in Period: Setmelanotide 2 mg QDRun-in Period: Setmelanotide 2.5 mg QDRun-in Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 20 mg QWDB Period: Setmelanotide 25 mg QWDB Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 30 mg QWOL Period: Setmelanotide 20 mg QWOL Period: Setmelanotide 25 mg QWOL Period: Setmelanotide 30 mg QW
Started21160000000
Completed21160000000
Not completed0000000000
Double Blind (DB) Period (13 Weeks)
Participant flow — Double Blind (DB) Period (13 Weeks)
MilestoneRun-in Period: Setmelanotide 2 mg QDRun-in Period: Setmelanotide 2.5 mg QDRun-in Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 20 mg QWDB Period: Setmelanotide 25 mg QWDB Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 30 mg QWOL Period: Setmelanotide 20 mg QWOL Period: Setmelanotide 25 mg QWOL Period: Setmelanotide 30 mg QW
Started0002197000
Completed0001177000
Not completed0001020000
Withdrew: Withdrawal by parent/guardian0001020000
Open Label (OL) Period (13 Weeks)
Participant flow — Open Label (OL) Period (13 Weeks)
MilestoneRun-in Period: Setmelanotide 2 mg QDRun-in Period: Setmelanotide 2.5 mg QDRun-in Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 20 mg QWDB Period: Setmelanotide 25 mg QWDB Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 30 mg QWOL Period: Setmelanotide 20 mg QWOL Period: Setmelanotide 25 mg QWOL Period: Setmelanotide 30 mg QW
Started00000001114
Completed00000001113
Not completed0000000001
Withdrew: Lack of efficacy0000000001

Outcome measures

PrimaryMaximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period

Maximum drug concentration determined directly from individual concentration-time data.

Time frame:
Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period
nanograms per milliliter (ng/mL)Setmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QD
Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period29.4 ± 3.4944.859.9 ± 29.6
PrimaryCmax of Setmelanotide After QW Administration

Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14
Reported as:
Mean · ng/mL
Cmax of Setmelanotide After QW Administration
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 30 mg QW (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Cmax of Setmelanotide After QW Administration22.432.731.8 ± 28.657.3 ± 33.0
PrimaryTime to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period

Maximum drug concentration determined directly from individual concentration-time data.

Time frame:
Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period
hoursSetmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QD
Time to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period6.91 (5.92 to 7.90)5.886.02 (2.00 to 8.00)
PrimaryTmax of Setmelanotide After QW Administration

Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14
Reported as:
Median · hours
Tmax of Setmelanotide After QW Administration
hoursSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 30 mg QW (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Tmax of Setmelanotide After QW Administration3.935.931.98 (0.500 to 6.00)5.95 (2.03 to 6.03)
PrimaryMean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 1

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 1
Reported as:
Mean · ng/mL
Mean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 1
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 15.17 ± 0.8564.3611.7 ± 13.516.6 ± 16.3
PrimaryMean Setmelanotide Ctrough After QD or QW Administration at Week 5

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 5
Reported as:
Mean · ng/mL
Mean Setmelanotide Ctrough After QD or QW Administration at Week 5
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Setmelanotide Ctrough After QD or QW Administration at Week 5—9.5412.2 ± 7.6215.6 ± 13.3
PrimaryMean Setmelanotide Ctrough After QD or QW Administration at Week 9

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 9
Reported as:
Mean · ng/mL
Mean Setmelanotide Ctrough After QD or QW Administration at Week 9
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Setmelanotide Ctrough After QD or QW Administration at Week 911.16.4312.3 ± 11.420.1 ± 13.7
PrimaryMean Setmelanotide Ctrough After QD or QW Administration at Week 18

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 18
Reported as:
Mean · ng/mL
Mean Setmelanotide Ctrough After QD or QW Administration at Week 18
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Setmelanotide Ctrough After QD or QW Administration at Week 1814.412.613.6 ± 13.926.2 ± 23.8
PrimaryMean Setmelanotide Ctrough After QD or QW Administration at Week 22

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 22
Reported as:
Mean · ng/mL
Mean Setmelanotide Ctrough After QD or QW Administration at Week 22
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Setmelanotide Ctrough After QD or QW Administration at Week 2211.914.317.0 ± 15.427.9 ± 25.4
PrimaryMean Setmelanotide Ctrough After QD or QW Administration at Week 27

Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
30 minutes predose at Week 27
Reported as:
Mean · ng/mL
Mean Setmelanotide Ctrough After QD or QW Administration at Week 27
ng/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 3 mg QD (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
Mean Setmelanotide Ctrough After QD or QW Administration at Week 2714.29.9120.3 ± 19.432.1 ± 23.9
PrimaryArea Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period

AUC0-tau was recorded from collected blood samples.

Time frame:
Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, and 8 hours postdose at Week -1
Reported as:
Mean · hours*ng/mL
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period
hours*ng/mLSetmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QD
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period——975 ± 659
PrimaryAUC0-tau of Setmelanotide After QD Administration in the Run-in Period

AUC0-tau was recorded from collected blood samples. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).

Time frame:
Pre-dose (0 hour) and 0.5, 1, 2, 6, 8, 12, 24, 48, 72, 96, 120, and 168-hours postdose at Week 14
Reported as:
Mean · hours*mg/mL
AUC0-tau of Setmelanotide After QD Administration in the Run-in Period
hours*mg/mLSetmelanotide 20 mg QW (QD-QW-QW)Setmelanotide 25 mg QW (QD-QW-QW)Setmelanotide 30 mg QW (QD-QD-QW)Setmelanotide 30 mg QW (QD-QW-QW)
AUC0-tau of Setmelanotide After QD Administration in the Run-in Period159022602470 ± 28905010 ± 4000
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The AEs reported after the start of the run-in period were considered TEAEs.

Time frame:
From first dose of study drug administration up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRun-in Period: Setmelanotide 2 mg QDRun-in Period: Setmelanotide 2.5 mg QDRun-in Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 20 mg QWDB Period: Setmelanotide 25 mg QWDB Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 30 mg QWOL Period: Setmelanotide 20 mg QWOL Period: Setmelanotide 25 mg QWOL Period: Setmelanotide 30 mg QW
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)00121960110
SecondaryNumber of Participants With Injection Site Reactions (ISRs) From Baseline Through Week 13

The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Baseline was defined as the last available measurement prior to the first dose of setmelanotide or placebo. Injection site reactions frequency of once daily (QD) and once weekly (QW) were reported. Data are reported by dose level (treatment regimen) in the DB Period. Number of participants with injection site reactions according to severity were reported.

Time frame:
Baseline through Week 13
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions (ISRs) From Baseline Through Week 13
ParticipantsSetmelanotide 20 mg QWSetmelanotide 25 mg QWSetmelanotide 3 mg QDSetmelanotide 30 mg QW
Erythema QD — None2075
Erythema QD — Mild0122
Erythema QD — Moderate0000
Erythema QD — Severe0000
Erythema QW — None1043
Erythema QW — Mild1143
Erythema QW — Moderate0011
Erythema QW — Severe0000
Edema QD — None2197
Edema QD — Mild0000
Edema QD — Moderate0000
Edema QD — Severe0000
Edema QW — None2196
Edema QW — Mild0001
Edema QW — Moderate0000
Edema QW — Severe0000
Induration QD — None1196
Induration QD — Mild1000
Induration QD — Moderate0001
Induration QD — Severe0000
Induration QW — None1084
Induration QW — Mild1112
Induration QW — Moderate0001
Induration QW — Severe0000
Itching QD — None2183
Itching QD — Mild0014
Itching QD — Moderate0000
Itching QD — Severe0000
Itching QW — None2192
Itching QW — Mild0004
Itching QW — Moderate0001
Itching QW — Severe0000
Pain or Tenderness QD — None2065
Pain or Tenderness QD — Mild0132
Pain or Tenderness QD — Moderate0000
Pain or Tenderness QD — Severe0000
Pain or Tenderness QW — None2061
Pain or Tenderness QW — Mild0132
Pain or Tenderness QW — Moderate0004
Pain or Tenderness QW — Severe0000
Other QD — None1197
Other QD — Mild1000
Other QD — Moderate0000
Other QD — Severe0000
Other QW — None0165
Other QW — Mild2031
Other QW — Moderate0001
Other QW — Severe0000
SecondaryNumber of Participants With ISRs From Week 14 Through Week 27

The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Injection site reactions frequency of QD and QW were reported. Data are reported by dose level (treatment regimen) in the OL Period. Number of participants with injection site reactions according to severity were reported.

Time frame:
Week 14 through Week 27
Reported as:
Count of participants · Participants
Number of Participants With ISRs From Week 14 Through Week 27
ParticipantsSetmelanotide 20 mg QWSetmelanotide 25 mg QWSetmelanotide 30 mg QW
Erythema QD — None1113
Erythema QD — Mild001
Erythema QD — Moderate000
Erythema QD — Severe000
Erythema QW — None1012
Erythema QW — Mild012
Erythema QW — Moderate000
Erythema QW — Severe000
Edema QD — None1113
Edema QD — Mild001
Edema QD — Moderate000
Edema QD — Severe000
Edema QW — None1114
Edema QW — Mild000
Edema QW — Moderate000
Edema QW — Severe000
Induration QD — None1113
Induration QD — Mild001
Induration QD — Moderate000
Induration QD — Severe000
Induration QW — None008
Induration QW — Mild114
Induration QW — Moderate002
Induration QW — Severe000
Itching QD — None1114
Itching QD — Mild000
Itching QD — Moderate000
Itching QD — Severe000
Itching QW — None1110
Itching QW — Mild004
Itching QW — Moderate000
Itching QW — Severe000
Pain or Tenderness QD — None1113
Pain or Tenderness QD — Mild001
Pain or Tenderness QD — Moderate000
Pain or Tenderness QD — Severe000
Pain or Tenderness QW — None118
Pain or Tenderness QW — Mild006
Pain or Tenderness QW — Moderate000
Pain or Tenderness QW — Severe000

Adverse events

Collected over From first dose of study drug administration up to week 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Period: Setmelanotide 2 mg QD0/2 (0%)0/2 (0%)0/2 (0%)
Run-in Period: Setmelanotide 2.5 mg QD0/1 (0%)0/1 (0%)0/1 (0%)
Run-in Period: Setmelanotide 3 mg QD0/16 (0%)0/16 (0%)1/16 (6.3%)
DB Period: Setmelanotide 20 mg QW0/2 (0%)0/2 (0%)2/2 (100%)
DB Period: Setmelanotide 25 mg QW0/1 (0%)0/1 (0%)1/1 (100%)
DB Period: Setmelanotide 3 mg QD0/9 (0%)0/9 (0%)9/9 (100%)
DB Period: Setmelanotide 30 mg QW0/7 (0%)0/7 (0%)6/7 (85.7%)
OL Period: Setmelanotide 20 mg QW0/1 (0%)0/1 (0%)0/1 (0%)
OL Period: Setmelanotide 25 mg QW0/1 (0%)0/1 (0%)1/1 (100%)
OL Period: Setmelanotide 30 mg QW0/14 (0%)0/14 (0%)10/14 (71.4%)
Most frequent other events
Showing 10 of 47
Most frequent other events
EventRun-in Period: Setmelanotide 2 mg QDRun-in Period: Setmelanotide 2.5 mg QDRun-in Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 20 mg QWDB Period: Setmelanotide 25 mg QWDB Period: Setmelanotide 3 mg QDDB Period: Setmelanotide 30 mg QWOL Period: Setmelanotide 20 mg QWOL Period: Setmelanotide 25 mg QWOL Period: Setmelanotide 30 mg QW
Injection site erythemaGeneral disorders0/20/11/161/21/14/92/70/11/10/14
Injection site painGeneral disorders0/20/10/160/21/14/95/70/11/11/14
Injection site indurationGeneral disorders0/20/10/161/21/12/92/70/11/11/14
NasopharyngitisInfections and infestations0/20/10/160/21/11/91/70/11/12/14
NauseaGastrointestinal disorders0/20/10/160/21/13/90/70/11/10/14
Skin hyperpigmentationSkin and subcutaneous tissue disorders0/20/10/160/21/12/90/70/11/11/14
AlopeciaSkin and subcutaneous tissue disorders0/20/10/160/20/10/90/70/11/10/14
Meniscus injuryInjury, poisoning and procedural complications0/20/10/160/20/10/90/70/11/10/14
CoughRespiratory, thoracic and mediastinal disorders0/20/10/160/21/10/90/70/10/11/14
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/20/10/160/21/10/91/70/10/11/14

Baseline characteristics

Full Analysis Set (FAS) included all participants who received at least 1 dose of setmelanotide after the randomization.

Age, Continuous
Age, Continuous(years)Setmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QDTotal
Mean20.0 ± 12.7319.020.8 ± 8.3020.6 ± 8.16
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QDTotal
Female011011
Male2068
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QDTotal
Hispanic or Latino0022
Not Hispanic or Latino211417
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Setmelanotide 2 mg QDSetmelanotide 2.5 mg QDSetmelanotide 3 mg QDTotal
Race — Asian1001
Race — White111416
Race — Other0022
08

Study locations

7 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • Marshfield Clinic Research Institute
    Marshfield, Wisconsin 54449, United States
  • Alberta Health Services
    Edmonton, Alberta T6G 2E1, Canada
  • Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Erasmus MC
    Rotterdam, 3015 CE, Netherlands
  • UPR Medical Sciences Campus
    Rio Piedras, 00935, Puerto Rico
  • Addenbrooke's Hospital
    Cambridge, CA2 0QQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Oct 2023, 21 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Jan 18, 2022
StartActual
Dec 21, 2021
Primary completionActual
Oct 19, 2023
CompletionActual
Oct 19, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05194124
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Dec 21, 2021
Primary completion
Oct 19, 2023
Completion
Oct 19, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion